Strang 1997.

Methods	Active vs placebo Pain measurement tool: VAS, patient reported
Participants	Prostate cancer, hormone refractory Bone metastases required Pain required (> 20 mm on VAS) Co‐intervention: none described Performance status criteria: life expectancy > 3 months Other criteria: exclude renal dysfunction, bisphosphonate within 1 month
Interventions	1. Active arm 1: Clodronate Intravenous, 300 mg/day x3 days then oral 600 mg twice a day x4 weeks 25 pts 2. Active arm 2: Placebo 27 pts
Outcomes	1. Pain: P value only 2. Analgesic: Not a reported endpoint Adverse effects: not reported
Notes	QS = 3 study closed early due to lack of accrual